From the Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; and China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China.
Stroke. 2015 Mar;46(3):864-6. doi: 10.1161/STROKEAHA.114.007979. Epub 2015 Feb 3.
The performance of the Totaled Health Risks in Vascular Events (THRIVE) score in predicting clinical outcomes in Chinese patients with acute ischemic stroke post intravenous thrombolysis is unknown.
Data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) study was used to compare the THRIVE score with other scores used to predict clinical outcomes and symptomatic intracranial hemorrhage after intravenous thrombolysis.
Among the 1128 patients with acute ischemic stroke who were included in this study, areas under the curve of the THRIVE score for symptomatic intracranial hemorrhage, 3-month poor functional outcomes, and death rate were 0.69, 0.71, and 0.78, respectively. The increased THRIVE score was related to the higher risk of developing symptomatic intracranial hemorrhage, poor functional outcomes, or death in patients with acute ischemic stroke at 3 months after thrombolysis.
The THRIVE score predicted reliably the risks of developing symptomatic intracranial hemorrhage, poor functional outcome, or death after intravenous thrombolysis therapy in Chinese patients with acute ischemic stroke.
THRIVE 评分预测接受静脉溶栓治疗的中国急性缺血性脑卒中患者临床结局的效能尚不清楚。
本研究使用中国急性缺血性脑卒中溶栓治疗监测(TIMS-China)研究的数据,比较 THRIVE 评分与其他用于预测静脉溶栓后临床结局和症状性颅内出血的评分。
本研究纳入了 1128 例急性缺血性脑卒中患者,THRIVE 评分预测症状性颅内出血、3 个月不良功能结局和死亡率的曲线下面积分别为 0.69、0.71 和 0.78。THRIVE 评分增加与溶栓后 3 个月患者发生症状性颅内出血、不良功能结局或死亡的风险增加相关。
THRIVE 评分可可靠地预测中国急性缺血性脑卒中患者接受静脉溶栓治疗后发生症状性颅内出血、不良功能结局或死亡的风险。